Trial · NCT02636699
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population | DBV712 250 μg | 35.3 | 95% Confidence Interval 29.5 to 41.6 | percentage of participants | |
| Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population | Placebo | 13.6 | 95% Confidence Interval 8.5 to 20.9 | percentage of participants | |
| Difference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening Eliciting Dose (ED) Subgroup | DBV712 250 μg | Screening ED subgroup 1 | 39.0 | 95% Confidence Interval 25.7 to 54.3 | percentage of participants |
| Difference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening Eliciting Dose (ED) Subgroup | Placebo | Screening ED subgroup 1 | 20.0 | 95% Confidence Interval 8.1 to 41.6 | percentage of participants |
| Difference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening Eliciting Dose (ED) Subgroup | DBV712 250 μg | Screening ED subgroup 2 | 34.5 | 95% Confidence Interval 28.2 to 41.4 | percentage of participants |
| Difference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening Eliciting Dose (ED) Subgroup | Placebo | Screening ED subgroup 2 | 12.2 | 95% Confidence Interval 7.1 to 20.2 | percentage of participants |
| Cumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12 | DBV712 250 μg | Baseline | 144.0 | Inter-Quartile Range 44.0 to 444.0 | mg |
| Cumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12 | Placebo | Baseline | 144.0 | Inter-Quartile Range 44.0 to 444.0 | mg |
| Cumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12 | DBV712 250 μg | Month 12 | 444.0 | Inter-Quartile Range 144.0 to 1444.0 | mg |
| Cumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12 | Placebo | Month 12 | 144.0 | Inter-Quartile Range 44.0 to 444.0 | mg |
| Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time | DBV712 250 μg | Month 3 | 78.716 | Inter-Quartile Range 26.557 to 174.588 | Percent of change |
| Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time | Placebo | Month 3 | 16.964 | Inter-Quartile Range -12.591 to 48.802 | Percent of change |
| Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time | DBV712 250 μg | Month 6 | 39.716 | Inter-Quartile Range -3.676 to 109.690 | Percent of change |
| Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time | Placebo | Month 6 | 4.605 | Inter-Quartile Range -26.380 to 30.352 | Percent of change |
| Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time | DBV712 250 μg | Month 12 | 2.858 | Inter-Quartile Range -24.739 to 61.058 | Percent of change |
| Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time | Placebo | Month 12 | -6.919 | Inter-Quartile Range -31.468 to 25.291 | Percent of change |
| Relative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time | DBV712 250 μg | Month 3 | 127.778 | Inter-Quartile Range 55.660 to 259.615 | Percent of change |
| Relative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time | Placebo | Month 3 | 14.286 | Inter-Quartile Range 0.000 to 45.833 | Percent of change |
| Relative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time | DBV712 250 μg | Month 6 | 258.491 | Inter-Quartile Range 107.843 to 549.351 | Percent of change |
| Relative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time | Placebo | Month 6 | 11.492 | Inter-Quartile Range -9.677 to 42.105 | Percent of change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02636699/results